Search
Breakthrough results in European multicenter trial on acute promyelocytic leukemia (APL): no more chemotherapy?
APL is a rare, yet aggressive, subtype of acute myeloid leukemia (AML) characterized by a maturation arrest of white blood cell precursors in the marrow, leading to a shortage of normal white cells and platelets in the blood, which is…
Read moreThe invisible burden of the pandemic
Writing about my perspective on the COVID-19 pandemic has been on my mind for some time.
Read moreSecure European Research Funding! Sign the Petition!
http://www. no-cuts-on-research. eu
EHA supports European Nobel and Fields Medal prizewinners to prevent the EU research funding for 2014-2020 from being subject to budget cuts.
Is CRTH for me?
Eligibility
Applicant must be a trainee or junior faculty and hold an MD or MD/PhD
Applicant must be actively employed in a hematology or hematology-related research environment
The applicant must be an EHA member or EHA Guest at the time of application submission…
A journey to hematology – a dream come true
YoungEHA proudly presents our first blog authored by a guest writer, Dr. Ana Zelić Kerep, a resident physician in the Department of Hematology, University Hospital Center Zagreb, Croatia. A journey to hematology – a dream come true
by Dr.
Current status of the Clinical Trials Regulation
HemAffairs Article #2 – June 2019
In 2014 the European Parliament approved the Clinical Trials Regulation (CTR) that is supposed to replace the Clinical Trials Directive (CTD) from 2001. Five years later, the regulation has not yet become applicable.